Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
about
Nanostructures for the Inhibition of Viral InfectionsDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryAccelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles.Long-acting slow effective release antiretroviral therapy.Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) EnzymesSystems Approach to targeted and long-acting HIV/AIDS therapy.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelNanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.Creation of a long-acting nanoformulated dolutegravir.Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.
P2860
Q26801513-D756D79E-7589-41E6-8883-F5EF38092D68Q28081272-AC97F46A-CAC4-4D2F-B08B-72D6E4691C68Q28821119-F3BAB02D-48C1-421F-BEC2-65ACC1AB23ADQ36205937-30F0797D-C289-4791-B6DC-081F3ABD4E27Q36262152-8C02DBF3-4F16-4583-BA28-3DE16DA0E195Q36338109-5D4DF499-8149-4E0C-B3FC-C5A1723230C9Q36783298-AC282FA8-6052-4160-89B0-0AA599D5AF19Q36933427-697B01B2-A3C6-4DE9-B1EE-BCB8EA32CAE3Q37013364-63ECFCEB-CE12-4AA6-B674-50A470EB93D3Q37538618-BC3D5816-4D48-416A-B2A5-6544392507F5Q37693640-254EF1E6-C905-4BB0-9447-6A541A3F4211Q39121184-8E382228-98DE-4A4A-BB4B-17C81F31C736Q47142890-34FCB8E5-0CA7-4A91-B583-1CA4BF7C6150Q47603651-9413B0C8-53EA-47C9-BCB3-C18AC7D5AD28Q47760026-8977DCD0-D8C7-4A29-BBF0-B89C817B849DQ50051618-B14DD17A-BD99-4303-8232-730ED2859A6CQ55338133-33C1B613-6063-4DEB-8FF1-4D95A786DC1F
P2860
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@ast
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@en
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@nl
type
label
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@ast
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@en
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@nl
prefLabel
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@ast
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@en
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@nl
P2093
P2860
P356
P1476
Anti-HIV drug-combination nano ...... h nodes and blood in primates.
@en
P2093
Cuiling Shu
Jennifer P Freeling
Jianguo Sun
Josefin Koehn
Rodney J Y Ho
P2860
P304
P356
10.1089/AID.2014.0210
P577
2015-01-01T00:00:00Z